Klotho Neurosciences, Inc. (KLTO)
KLTO Stock Price Chart
Explore Klotho Neurosciences, Inc. interactive price chart. Choose custom timeframes to analyze KLTO price movements and trends.
KLTO Company Profile
Discover essential business fundamentals and corporate details for Klotho Neurosciences, Inc. (KLTO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Apr 2022
Employees
3.00
Website
https://klothoneuro.comCEO
Joseph Sinkule
Description
Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.
KLTO Financial Timeline
Browse a chronological timeline of Klotho Neurosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 18 Aug 2025
EPS came in at -$0.12 .
Earnings released on 31 Mar 2025
EPS came in at -$0.07 .
Earnings released on 25 Feb 2025
Earnings released on 19 Nov 2024
EPS came in at -$0.18 .
Earnings released on 19 Aug 2024
EPS came in at -$0.03 .
Earnings released on 30 Jun 2024
EPS came in at -$0.03 .
Earnings released on 31 Dec 2023
EPS came in at -$0.00 .
Earnings released on 30 Sept 2023
EPS came in at -$0.00 .
Earnings released on 30 Jun 2023
EPS came in at -$0.00 .
Earnings released on 30 Jun 2022
EPS came in at -$0.00 .
KLTO Stock Performance
Access detailed KLTO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.